

Prevalence of Microorganisms Isolated in Blood Cultures Samples from Patients from a Private Hospital in Juiz de Fora, Minas Gerais

Prevalência de Micro-Organismos Isolados em Amostras de Hemoculturas de Pacientes de Um Hospital Privado De Juiz de Fora - Mg

Mayara Silveira Leal¹, Patrícia Ganimi Tavella¹, Patrícia Guedes Garcia²

¹ Estudante do Programa de Pós – Graduação em Análises Clínicas da Faculdade de Ciências Médicas e da Saúde de Juiz de Fora – SUPREMA.

² Doutora, Professora da Faculdade de Ciências Médicas e da Saúde de Juiz de Fora – SUPREMA.

*Mayara Silveira Leal. Email: myrsilveira@gmail.com

ABSTRACT

Objectives: To evaluate the prevalence of microorganisms isolated from blood cultures samples from the Intensive Care Units and Coronary Unit; Define the profile of susceptibility to antimicrobial strains of isolated bacterial strain. **Methods:** Were data collected from all positive blood cultures of ICU's Adult, Neonatal and UC in a private hospital in Juiz de Fora, Minas Gerais, Brazil, from January 2017 to January 2019. **Results:** 3536 samples from blood cultures were found, where 2464 (69,7%) were negative and 1072 (30,3%) were positive for some microorganism. Among the positive samples, a higher prevalence was observed among males (540/50,4%). The most prevalent microorganisms were Staphylococcus sp coagulase negativa (55,5%), Klebsiella pneumoniae (7,2%), Staphylococcus aureus (5,4%), Serratia marcescens (4,7%), Escherichia coli (3,9%), Acinetobacter baumannii (3,6%), Pseudomonas aeruginosa (2,4%), Gram-positive bacilli (2,4%), Candida parapsilosis (2,2%), Enterobacter cloacae (2,0%), Enterococcus faecalis (1,4%) and Candida albicans (1,3%). Among the Gram-positive bacteria, erythromycin, along with oxacilin, clindamycin and quinolones, were the antimicrobials with the highest degree of resistance. Among the Gram-negative drugs, cephalosporins and quinolones were the least effective drugs, although carbapenems showed an important resistance. **Conclusion:** This study alerts to the high degree of multidrug resistance to antimicrobial strains from ICU and UC, and to the increasing development of negative coagulase species in blood cultures, demonstrating a current worrying scenario and the need development of new drugs and new control measures.

Keywords: Sepsis; Bacterial drug resistance; Antimicrobial susceptibility testing.

RESUMO

Objetivos: Avaliar a prevalência de micro-organismos isolados de amostras de hemoculturas provenientes das Unidades de Terapia Intensiva; Definir o perfil de suscetibilidade aos antimicrobianos das cepas bacterianas isoladas. **Métodos:** Foram coletados dados de todas as hemoculturas positivas das UTI's Adulto, Neonatal e UC de um hospital privado, em Juiz de Fora, Minas Gerais, Brasil, de janeiro de 2017 a janeiro de 2019. **Resultados:** Foram encontradas 3536 amostras de hemoculturas onde 2464 (69,68%) foram negativas e 1072 (30,32%) positivas para algum micro-organismo. Dentre as amostras positivas, observou-se prevalência entre o sexo masculino (540/50,4%). Os microrganismos prevalentes foram: Staphylococcus sp coagulase negativa (55,5%), Klebsiella pneumoniae (7,2%), Staphylococcus aureus (5,4%), Serratia marcescens (4,7%), Escherichia coli (3,9%), Acinetobacter baumannii (3,6%), Pseudomonas aeruginosa (2,4%), Bastonetes Gram positivos (2,4%), Candida parapsilosis (2,2%), Enterobacter cloacae (2,0%), Enterococcus faecalis (1,4%) e Candida albicans (1,3%). Dentre as bactérias Gram positivas, a eritromicina, juntamente com a oxacilina, clindamicina e as quinolonas, foram os antimicrobianos que apresentaram maior grau de resistência. Já entre os Gram negativos, as cefalosporinas e quinolonas foram as drogas menos efetivas, apesar de os carbapenêmicos terem apresentado uma resistência importante. **Conclusão:** o presente estudo alerta para o elevado grau de multirresistência aos antimicrobianos das cepas advindas das UTI's e UC, e ao crescente desenvolvimento de espécies coagulase negativas em hemoculturas, demonstrando um cenário atual preocupante e a necessidade de desenvolvimento de novas drogas e novas medidas de controle

Palavras-chave: Sepsis; Farmacorresistência Bacteriana; Testes de Sensibilidade a Antimicrobianos por Disco-Difusão.

INTRODUCTION

Bloodstream infections (BSI) are related to unfavorable health outcomes. In Brazil, through the Brazilian SCOPE study, about 40% of mortality was observed among patients with BSI¹. The presence of bacteria or fungi in the bloodstream is called bacteremia and fungemia, respectively². Intravascular devices, genitourinary tract, respiratory tract, intestine, biliary tract, intra-abdominal abscess, and unknown sites are the most common sources of BSI^{3,4}.

The body's response to the infectious agent occurs through signs and symptoms of the disease, such as the systemic inflammatory response syndrome, regardless of whether blood culture is positive or not. This set of responses is called sepsis. This, in turn, promotes organic dysfunction and puts the patient's life at risk. Despite the precariousness of studies on incidence and prevalence related to sepsis in Brazil, it is known that this syndrome is considered a major public health problem in intensive care units (ICUs), generating high costs for health systems^{3,5,6}.

The blood culture test is the gold standard for the detection of microorganisms in the blood. This has a high predictive value of infection since it is possible to detect the presence of viable microorganisms in the bloodstream. Its positivity is a relevant indicator of BSI and the identification of the causative pathogen is of utmost importance since it helps in the therapeutic choice^{3,5}. Therefore, inadequate therapeutic regimens induce selective pressure, which results in increased resistant strains, increased hospitalization costs, and higher mortality rates, especially in critically ill patients^{6,7,8,9}.

In view of the above, the aim of the present study was to assess the prevalence of isolated microorganisms in blood samples from patients in the ICUs and Coronary Care Unit (CCU) of a private hospital in the city of Juiz de Fora, Minas Gerais, and to evaluate the susceptibility profile to the antimicrobials of the isolated bacterial strains, thus contributing to research in the area of prevention of BSI, in addition to encouraging the Rational Use of Medicines.

METHODS

This is a descriptive, cross-sectional retrospective study and aimed to analyze blood culture samples performed in the clinical analysis laboratory of a private hospital located in the city of Juiz de Fora, Minas Gerais, from January 2017 to January 2019.

As an inclusion criterion, all samples of positive blood cultures were considered. The data that are part of the research were obtained through the digital files of the laboratory software Shift Lis® used by the laboratory. As this is a statistical analysis of data from exams already performed, this research represents minimal risks to patients, but significant in relation to the manipulation of digital data.

This study was previously approved by the Research Ethics Committee in accordance with Resolution 196/96 of the National Health Council under Opinion number 3.735.713.

The included blood cultures were automatically detected by the BACT/ALERT® 3D 60 device from bioMérieux, with subsequent identification and antibiogram in the Vitek® 2 Compact system from bioMérieux with GN identification cards for Gram-negative fermenters and non-fermenters with antibiogram cards AST-N238 and AST-N239, GP for Gram-positive and its complementary antibiogram card AST-P585, in addition to the YST for yeast identification¹⁰.

RESULTS

A total of 3536 blood culture samples were collected from the ICUs and CCUs over a two-year period, 2590 (73.3%) from the Adult ICU, 540 (15.3%) from the Neonatal ICU and 406 (11.5%) from the CCU. Of the total samples collected, 1072 (30.3%) showed positive growth and included the present study.

According to Table 1, among the samples analyzed, 540 (50.4%) were male patients, while 532 (49.6%) were female. It was also observed that more than 80% of the patients were 60 years old or older.

In the Adult ICU, 865 samples were positive, which correspond to 80.7% of the total samples analyzed. The rest of the samples came from CCU (113/10.5%) and Neonatal ICU (94/8.8%).

Of the 1072 samples studied, 44 showed concomitant growth of two microorganisms, totaling 1116 isolated microorganisms. Of these, 704 (63.1%) were Gram-positive cocci, 327 (29.3%) were morphotintorially classified as Gram-negative rods, 58 (5.2%) presented as fungal forms and 27 (2.4%) like Gram-positive rods.

According to Table 2, the prevalent microorganisms were: *Staphylococcus* sp.coagulase-negative (55.5%), *Klebsiella pneumoniae* (7.2%), *Staphylococcus aureus* (5.4%), *Serratia marcescens* (4.7%), *Escherichia coli* (3.9%), *Acinetobacter baumannii* (3.6%), *Pseudomonas aeruginosa* (2.4%), Gram-positive rods (2.4%), *Candida parapsilosis* (2.2%), *Enterobacter cloacae* (2.0%), *Enterococcus faecalis* (1.4%) and *Candida albicans* (1.3%).

The isolates belonging to the genus *Staphylococcus* sp.were prevalent (666/59.7%), followed by the order Enterobacteriales (237/21.2%), Gram-negative non-fermenting rods (78/7.0%), fungi (57/5.1%), Gram-positive bacilli (27/2.4%), and Gram-positive cocci of the genus *Enterococcus* sp. (19/1.7%) as described in Table 2.

Among staphylococci, in Table 3 we have their sensitivity profile, where the greatest resistance found was oxacillin (82.9%), followed by erythromycin (76.7%). As for quinolones, 78.3% of staphylococci were resistant to norfloxacin, 72.6% to ciprofloxacin, 68.6% to levofloxacin and 50.8% to moxifloxacin.

Table 1 . Demographic characteristics of the sample

	n= 1072 /100 %
Gender	
Male	540/50.4%
Female	532/49.6%
Age	
Less than 1 year	11/ 1.0%
From 1 to 9 years old	75/7.0%
From 10 to 19 years old	12/1.1%
From 20 to 29 years old	14/1.3%
From 30 to 39 years old	22/2.0%
From 40 to 49 years old	11/1.0%
From 50 to 59 years old	63/6.0%
From 60 to 69 years old	165/15.4%
From 70 to 79 years old	240/22.4%
Older than or equal to 80 years old	459/42.8%

Source: Elaborated by the authors

In the susceptibility test to antimicrobials, microorganisms belonging to the order Enterobacteriales had a high resistance index. Among cephalosporins, 74.3% showed resistance to cefuroxime, 61.5% to cephalothin, 58.2% to ceftriaxone, 55.8% to ceftazidime, and 53.6% to cefepime. Regarding quinolones, 46.2% of enterobacteria showed resistance to nalidixic acid, 41.8% to ciprofloxacin, and 23.1% to norfloxacin; 82.1% of the strains were resistant to ampicillin and 68.1% to ampicillin with sulbactam; 23.1% were resistant to sulfamethoxazole with trimethoprim; 19.8% of enterobacteria were resistant to amikacin and gentamicin. It was also observed a high resistance of these enterobacteria to carbapenems, where 40.1% were resistant to meropenem, 30.7% to imipenem, and 2.1% to ertapenem. Finally, 57.4% were resistant to ceftazidime, 38.5% to nitrofurantoin, 35.9% to piperacillin with tazobactam, 30.3% to colistin, and 10.9% to tigecycline. Such data were described in Table 4.

Of the 237 isolated enterobacteria, 14.4% (34/237) had a beta-lactamase resistance mechanism of the extended-spectrum (ESBL). Of these, 73.5% (25/34) were *K. pneumoniae* and 26.5% (9/34) *E. coli*.

In the analysis of the antimicrobial susceptibility profile of non-fermenting Gram-negative rods, a high percentage of resistance was observed. Among cephalosporins, 100% of the strains analyzed were resistant to cefuroxime, 76.3% to ceftriaxone, 67.1% to cefepime, and 65.4% to ceftazidime. As for quinolones, 100% of the non-fermenters were resistant to nalidixic acid, levofloxacin, and norfloxacin, while 68% were resistant to ciprofloxacin. Regarding aminoglycosides, 48.7% of the bacteria showed resistance to gentamicin and 31.4% to amikacin. Among the carbapenems, 66.7% were resistant to imipenem and 40% to meropenem. 100% of the strains were resistant to nitrofurantoin, ceftazidime, and amoxicillin with clavulanic acid. The resistance of these non-fermenters extends to tigecycline and piperacillin with tazobactam with 39.2% and 6.6% resistance, respectively, according to Table 5.

Among the 19 strains of isolated enterococci, 100% showed resistance to clindamycin, streptomycin, and high-concentration gentamicin. Among quinolones, it was observed that 100% of the bacteria were resistant to moxifloxacin, 63.2% to norfloxacin, and 42.1% to ciprofloxacin. In addition to these antimicrobials, some strains were also tested for vancomycin and ampicillin, with 100% of them showing resistance to vancomycin and 10.5% to ampicillin, as described in Table 6.

DISCUSSION

In a study by Rodríguez et al. (2011) 1045 blood cultures of clinical interest were analyzed, of which 375 (35%) were positive for some pathogen and 670 (65%) were negative. According to Chen et al. (2015) and Weiss et al. (2016), the proportionality of positivity of blood cultures remains, where the rate of positivity varies between 10% and 30%. Thus, it is possible to state that the results obtained in the present study were compatible: Of the total of 3536 blood culture samples, 2464 (69.7%) had a negative result, while 1072 (30.3%) were positive for the growth of some microorganism.

The present study showed that the positive blood cultures analyzed had a higher incidence in males 540 (50.7%) compared to females 532 (49.3%). Corroborating this result is the study performed by Sousa et al. (2014) in which test results from 170 positive blood cultures of patients hospitalized in the ICU were evaluated, where about 56.0% were male and 43.0% of women. According to Couto et al. (2011), this is probably due to the fact that female hormones, especially estrogen, promote a better immune response to women. In addition, Wang et al. (2015) showed that about 60.0% of severe sepsis occurred in patients over 60 years of age, calling attention to the high percentage of elderly people with positive blood cultures found in this study.

According to Morello et al. (2019) and Takeshita et al. (2019) coagulase-negative staphylococci were the most commonly isolated

Table 2 . Prevalence of microorganisms

	n=1116 /100%	
<i>Staphylococcus sp coagulase negativa</i>	619	55.5%
<i>Klebsiella pneumoniae</i>	80	7.2%
<i>Staphylococcus aureus</i>	60	5.4%
<i>Serratia marcescens</i>	52	4.7%
<i>Escherichia coli</i>	43	3.9%
<i>Acinetobacter baumannii complex</i>	40	3.6%
<i>Pseudomonas aeruginosa</i>	27	2.4%
<i>Bacilos Gram Positivos</i>	27	2.4%
<i>Candida parapsilosis</i>	25	2.2%
<i>Enterobacter cloacae</i>	22	2.0%
<i>Enterococcus faecalis</i>	16	1.4%
<i>Candida albicans</i>	14	1.3%
<i>Proteus mirabilis</i>	11	1.0%
<i>Enterobacter aerogenes</i>	8	0.7%
<i>Candida glabrata</i>	7	0.6%
<i>Candida famata</i>	7	0.6%
<i>Providencia stuartii</i>	4	0.4%
<i>Pseudomonas putida</i>	4	0.4%
<i>Staphylococcus sp. alfa hemolítico</i>	3	0.3%
<i>Micrococcus luteus</i>	3	0.3%
<i>Morganella morganii</i>	3	0.3%
<i>Grupo Salmonella</i>	3	0.3%
<i>Burkholderia cepacea</i>	3	0.3%
<i>Stenotrophomonas maltophilia</i>	2	0.2%
<i>Streptococcus pyogenes</i>	2	0.2%
<i>Staphylococcus anginosus</i>	2	0.2%
<i>Klebsiella xyloca</i>	2	0.2%
<i>Enterobacter gergoviae</i>	2	0.2%
<i>Enterococcus faecium</i>	2	0.2%
<i>Citrobacter braaki</i>	2	0.2%
<i>Acinetobacter Iwoffii</i>	2	0.2%
<i>Actinomyces naeslundii</i>	2	0.2%
<i>Sphingomonas paucimobilis</i>	1	0.1%
<i>Streptococcus salivarius</i>	1	0.1%
<i>Serratia rubidea</i>	1	0.1%
<i>Streptococcus pneumoniae</i>	1	0.1%
<i>Streptococcus mitis</i>	1	0.1%
<i>Serratia fonticola</i>	1	0.1%
<i>Streptococcus agalactiae</i>	1	0.1%
<i>Paenibacillus macerans</i>	1	0.1%
<i>Pseudomonas stutzeri</i>	1	0.1%
<i>Kocuria kristinae</i>	1	0.1%
<i>Enterococcus gallinarum</i>	1	0.1%
<i>Enterobacter asburiae</i>	1	0.1%
<i>Citrobacter freudii</i>	1	0.1%
<i>Candida haemulonii</i>	1	0.1%
<i>Candida guilliermondii</i>	1	0.1%
<i>Aeromonas hydrophila</i>	1	0.1%
<i>Streptococcus sobrinus</i>	1	0.1%

Fonte: elaborada pelos autores.

Table 3 . Staphylococcus susceptibility profile

	R	I	S
AMP	5/12 (41.7%)		7/12 (58.3%)
FUS	101/597 (16.9%)	96/597 (16.1%)	400/597 (67.0%)
CIP	440/606 (72.6%)	35/606 (5.8%)	131/606 (21.6%)
LVX	35/51 (68.6%)		16/51 (31.4%)
GEN	197/654 (30.1%)	60/654 (9.2%)	397/654 (60.7%)
NOR	470/600 (78.3%)	3/600 (0.5%)	127/600 (21.2%)
NIT	1/51 (2.0%)		50/51 (98.0%)
SUT	1/66 (1.5%)		65/66 (98.5%)
TIG			637/637 (100.0%)
CLI	434/655 (66.3%)	23/655 (3.5%)	198/655 (30.2%)
ERI	511/666 (76.7%)	6/666 (0.9%)	149/666 (22.4%)
DAP			5/5 (100.0%)
OXA	542/654 (82.9%)		112/654 (17.1%)
PEN	8/15 (53.3%)		7/15 (46.7%)
LNZ	1/485 (0.2%)		484/485 (99.8%)
RIF	110/653 (16.8%)	21/653 (3.2%)	522/653 (80.0%)
VAN	2/664 (0.3%)		662/664 (99.7%)
MOX	303/597 (50.8%)	166/597 (27.8%)	128/597 (21.4%)
TEC			7/7 (100.0%)

Source: Elaborated by the authors.

Legend: R - Resistant; I - Intermediate; S - Sensitive; AMP -Ampicillin; CIP - Ciprofloxacin; CLI - Clindamycin; DAP - Daptomycin; ERI -Erythromycin; FUS: Fusidic acid; GEN - Gentamycin; LVX - Levofloxacin; LNZ - Linezolid; MOX - Moxifloxacin; NOR - Norfloxacin; NIT - Nitrofurantoin; OXA - Oxacillin; PEN - Penicillin G; RIF - Rifampicin; TEC - Teicoplanin; TIG - Tigecycline; VAN - Vancomycin; SUT - Sulfamethoxazole with trimethoprim.

Table 4 . Enterobacteriales susceptibility profile

	R	I	S
AMI	47/237 (19.8%)	8/237 (3.4%)	182/237 (76.8%)
AMC	6/13 (46.2%)		7/13 (53.8%)
NAL	6/13 (46.2%)		7/13 (53.8%)
AMP	119/145 (82.1%)	1/145 (0.7%)	25/145 (17.2%)
CFL	8/13 (61.5%)		5/13 (38.5%)
CIP	99/237 (41.8%)	25/237 (10.5%)	113/237 (46.7%)
COM	127/237 (53.6%)	4/237 (1.7%)	106/237 (44.7%)
CRO	138/237 (58.2%)		99/237 (41.8%)
CRX	176/237 (74.3%)	9/237 (3.8%)	52/237 (21.9%)
ERT	3/146 (2.1%)		143/146 (97.9%)
GEN	47/237 (19.8%)	3/237 (1.3%)	187/237 (78.9%)
MER	95/237 (40.1%)		142/237 (59.9%)
NOR	3/13 (23.1%)		10/13 (76.9%)
NIT	5/13 (38.5%)	2/13 (15.4%)	6/13 (46.1%)
PPT	65/181 (35.9%)	13/181 (7.2%)	103/181 (56.9%)
SUT	3/13 (23.1%)		10/13 (76.9%)
SBA	94/138 (68.1%)	5/138 (3.6%)	39/138 (28.3%)
CAZ	125/224 (55.8%)	6/224 (2.7%)	93/224 (41.5%)
CFO	128/223 (57.4%)	7/223 (3.1%)	88/223 (39.5%)
IPM	50/163 (30.7%)	5/163 (3.1%)	108/163 (66.2%)
TIG	18/165 (10.9%)	3/165 (1.8%)	144/165 (87.3%)
COL	69/228 (30.3%)		159/228 (69.7%)

Legend: R - Resistant; I - Intermediate; S - Sensitive

AMI - Amikacin; AMC - Amoxicillin with clavulanate; AMP - Ampicillin, COL - Colistin; CFL - Cephalothin; CIP - Ciprofloxacin; CPM - Cefepime; CAZ - Ceftazidime; CFO - Cefoxitin; CRO - Ceftriaxone; CRX - Cefuroxime; ERT - Ertapenem; GEN - Gentamycin; IPM - Imipenem; MER - Meropenem; NAL - Nalidixic acid; NOR - Norfloxacin; NIT - Nitrofurantoin; PPT - Piperacillin with tazobactam; SUT - Sulfamethoxazole with trimethoprim; SBA - Ampicillin with sulbactam; TIG - Tigecycline.

Table 5 . Non-fermentation susceptibility profile

	R	I	S
AMI	11/35 (31.4%)		24/35 (68.6%)
AMC	2/2 (100.0%)		
NAL	2/2 (100.0%)		
AMP	73/74 (98.6%)		1/74 (1.4%)
CIP	53/78 (68.0%)		25/78 (32.0%)
LVX	1/1 (100.0%)		
COM	51/76 (67.1%)	4/76 (5.3%)	21/76 (27.6%)
CRO	58/76 (76.3%)	14/76(18.4%)	4/76 (5.3%)
CRX	74/74 (100.0%)		
GEN	36/74 (48.7%)	6/74 (8.1%)	32/74 (43.2%)
MER	14/35 (40.0%)		21/35 (60.0%)
NOR	2/2 (100.0%)		
NIT	2/2 (100.0%)		
PPT	1/15 (6.6%)	4/15 (26.7%)	10/15 (66.7%)
SUT	2/7 (28.6%)		5/7 (71.4%)
SBA	60/74 (81.0%)	7/74 (9.5%)	7/74 (9.5%)
CAZ	51/78 (65.4%)	3/78 (3.8%)	24/78 (30.8%)
CFO	72/72 (100.0%)		
IPM	48/72 (66.7%)		24/72 (33.3%)
TIG	29/74 (39.2%)	10/74 (13.5%)	35/74 (47.3%)
COL			73/73 (100.0%)

Source: Elaborated by the authors.

Legend: R - Resistant; I - Intermediate; S - Sensitive AMI - Amikacin, AMC - Amoxicillin with clavulanate; AMP - Ampicillin; CIP - Ciprofloxacin; CPM - Cefepime; CAZ - Ceftazidime; COL - Colistin; CFO - Cefoxitin; CRO - Ceftriaxone; CRX - Cefuroxime; GEN - Gentamicin; IPM - Imipenem; LVX-Levofloxacin; MER - Meropenem; NOR - Norfloxacin; NIT- Nitrofurantoin; NAL - Nalidixic acid; PPT - Piperacillin with tazobactam; SUT - Sulfamethoxazole with trimethoprim; SBA - Ampicillin with sulbactam; TIG - Tigecycline.

Table 6 - Profile of susceptibility of enterococci

	R	I	S
AMP	2/19 (10.5%)		17/19 (89,5%)
CIP	8/19 (42.1%)	2/19 (10.5%)	9/19 (47,4%)
NOR	12/19 (63.2%)		7/19 (36,8%)
TIG			19/19 (100,0%)
CLI	19/19 (100.0%)		
ERI	11/19 (58.0%)	4/19 (21.0%)	4/19 (21,0%)
EST-H	7/7 (100.0%)		
GEN-H	8/8 (100.0%)		
VAN	2/2 (100.0%)		
MOX	6/6 (100.0%)		

Source: Elaborated by the authors

Legend: R - Resistant; I - Intermediate; S - Sensitive AMP - Ampicillin; CIP - Ciprofloxacin; CLI - Clindamycin; ERI - Erythromycin; EST-H - High concentration streptomycin; GEN-H - High concentration gentamicin; LNZ - Linezolid; MOX - Moxifloxacin; NOR - Norfloxacin; TIG - Tigecycline; VAN - Vancomycin.

pathogens and the high prevalence of these can be confirmed during the study, with the isolation of 619 species, representing 55.46% of the total pathogens isolated from blood cultures. According to Park et al. (2015), coagulase-negative staphylococci are responsible for 20 to 30% of infections in critically ill patients and are generally associated with central catheters and implantable devices. The high prevalence of these microorganisms indicates a possible contamination at the time of collection, since this pathogen can be found in several sites on the body, including the composition of the

skin microbiota. However, due to the retrospective nature of this study, it was not possible to assess whether the detection of this pathogen was due to infection or contamination of the samples.

As for the profile of susceptibility to antimicrobials, a study by Ruschel et al. (2017) found high staphylococcal resistance to oxacillin, erythromycin, clindamycin, and quinolones, corroborating the research.

The main Gram-negative bacilli found in the present study were *Klebsiella pneumoniae*, *Serratia marcescens*, *Escherichia coli* and *Enterobacter cloacae*. This prevalence was similar to that reported by

Basso et al. (2016), Mota et al. (2018), and Uc-Cachón et al. (2019), where among the main pathogens classified as Gram-negative bacilli were *Klebsiella pneumoniae* and *Escherichia coli*.

The high rate of resistance of enterobacteria to cephalosporins, quinolones, aminoglycosides, and carbapenems described in this study are similar to those reported in a study performed in a teaching hospital by Parajuli et al. (2017) and according to UC-Cachón et al. (2019), the high rate of resistance to cephalosporins is confirmed.

As for the production of ESBL, the study showed a low percentage (14.4%), differing from the study by Myat et al. (2017), who found about 38%. However, both studies found a prevalence of *Klebsiella pneumoniae* among strains producing extended-spectrum beta-lactamase, followed by *Escherichia coli*.

The prevalence found of non-fermenting Gram-negative rods was *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, the same as reported by Basso et al. (2016), Mota et al. (2018). In addition, the high rate of resistance to quinolones, cephalosporins, aminoglycosides, carbapenems described in this study, is similar to that described by Moolchandani et al. (2017), where the non-fermenters isolated by them showed resistance to the same classes of antimicrobials.

When it comes to fungemia, it is noted that the main associated fungus is *Candida albicans* (19,21,22,23). In Brazil, the survey of epidemiological data on fungemias in communities and hospitals has become increasingly frequent. In their study, Motta et al. (2010), reported a prevalence of 4% of fungemia in blood cultures with approximately 86% of cases related to species of the genus *Candida* sp. However, according to Silva et al. (2015), the current scenario has been showing an increase in the incidence of candidemia caused by non-*albicans* species, mainly by *Candida parapsilosis*. Such studies are in agreement with the present study since it was observed a prevalence of about 5% of forms fungi in the positive blood cultures analyzed, with a greater frequency of the species *Candida parapsilosis* and *Candida albicans*.

According to Arias et al. (2010) the most effective lactam beta against infections caused by enterococci is ampicillin, corroborating the study since this antimicrobial showed 89.5% sensitivity. High sensitivity to tigecycline is also noted, reaffirming the choice of this drug as a treatment alternative. However, Arias et al. warn that the prescription of such a drug should be done with caution since cases of resistance have already been reported.

CONCLUSION

Therefore, it was noted that the prevalence of negative coagulase *Staphylococcus* was prevalent, which serves as a warning for a possible infection caused by this microorganism, and should be analyzed together with the patient's clinic, since, according to

the current literature, they are responsible for contamination of blood cultures, resulting from collection errors. In order to discover the real etiology of these infections, it is necessary to emphasize the correct asepsis of the professionals' hands in order to maintain patient safety and quality of the final result of the sample.

The study revealed a relevant prevalence of fermenting and non-fermenting enterobacteria with a high resistance profile to most of the antimicrobials used in medical practice, which encourages the rational use of medications.

New drugs and new control measures are needed, given that this growing resistance has become a worldwide public health problem.

REFERENCES

1. Agência Nacional de Vigilância Sanitária. Medidas de Prevenção de Infecção Relacionada à Assistência à Saúde. Brasília: Agência Nacional de Vigilância Sanitária, 2010.
2. Castro LL, Schutze M, Bucker DH, Vasconcellos LS. Prevalence of fungemia in a tertiary hospital: Analysis of the last decade. *Rev Assoc Med Bras.* 2016; 62(4): 315-319.
3. Araujo MRE. Hemocultura: recomendações de coleta, processamento e interpretação de resultados. *J Infect Control.* 2012; 1(1): 08-19.
4. Klingspor L, Ullberg M, Rydberg J, Kondori N, Serrander L, Swanberg J et al. Epidemiology of fungaemia in Sweden: A nationwide retrospective observational survey. *Mycoses.* 2018; 6: 777-785.
5. Ferreira LE, Dalposso K, Hackbarth BB, Gonçalves AR, Westphal GA, França PHC et al. Pannel molecular para detecção de microrganismos associados à sepse. *Rev Bras Ter Intensiva.* 2011; 23(1): 36-40.
6. Sitnik R, Marra AR, Petroni RC, Ramos OPS, Martino MDV, Pasternak Jat et al. Uso do SeptiFast para diagnóstico de sepse em doentes graves de um hospital brasileiro. *Einstein.* 2014; 12(2): 191-7.
7. Sociedade Brasileira de Patologia Clínica. Recomendações da Sociedade Brasileira de Patologia Clínica/Medicina Laboratorial (SBPC/ML): Boas práticas em microbiologia clínica. Barueri: Sociedade Brasileira de Patologia Clínica, 2015.
8. Siqueira JPZ, Almeida MAG. Molecular biology as a tool for fungal detection on blood: diagnostic aid and cost reduction. *Arch. Helth. Sci.* 2018; 25(3): 41-45.
9. Giolo MP, Svidzinski TIE. Fisiopatogenia, epidemiologia e diagnóstico laboratorial da candidemia. *J Bras Patol Med Lab.* 2010; 46: 225-34.
10. bioMérieux Brasil. Produtos e Serviços. Disponível em: URL: <http://www.biomerieux.com.br/diagnostico-clinico/produtos-e-servicos>. Acesso em 3 dezembro 2019.
11. Basso ME, Pulcinelli RSR, Aquino ARC, Santos KF. Prevalência de infecções bacterianas em pacientes internados em uma unidade de terapia intensiva (UTI). *Rev Bras Anal Clin.* 2016; 48(4): 383-88.
12. Mota FS, Oliveira HÁ, Souto RCF. Perfil e prevalência de resistência aos antimicrobianos de bactérias Gram-negativas isoladas de pacientes de uma unidade de terapia intensiva. *Rev Bras Anal Clin.* 2018; 50(3): 270-2.

13. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, Singhi SC, Erickson S, Roy JA, Bush JL, Nadkarni VM, Thomas NJ; Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. *Am J Respir Crit Care Med.* 2015; 191(10):1147-57. Erratum in: *Am J Respir Crit Care Med.* 2016; 193(2):223-4.
14. Chen XC, Yang YF, Wang R, Gou HF, Chen XZ. Epidemiology and microbiology of sepsis in mainland China in the first decade of the 21st century. *Int J Infect Dis.* 2015; 3: 9-14.
15. Park SY, Kwon KH, Chung JW, Huh HJ, Chae SL. Coagulase-negative staphylococcal bacteremia: risk factors for mortality and impact of initial appropriate antimicrobial therapy on outcome. *Eur J Clin Microbiol Infect Dis.* 2015; 34(7):1395-401.
16. Rodríguez F, Barrera L, De La Rosa G, Dennis R, Duenas C, Granados M, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. *Crit Care Med.* 2011;39(7):1675-82.
17. Uc-Cachón AH, Osorno CG, Luna-Chi IG, Guillermo JGJ, Salinas GMM. High Prevalence of Antimicrobial Resistance Among Gram-Negative Isolated Bacilli in Intensive Care Units at a Tertiary-Care Hospital in Yucatán Mexico. *Medicina.* 2019, 55, 588.
18. Morello LG, Dalla-Costa LM, Fontana RM, Netto ACSO, Petterle RR, Conte D, Pereira LA, Krieger MA, Raboni SM. Avaliação das características clínicas e epidemiológicas de pacientes com e sem sepse nas unidades de terapia intensiva de um hospital terciário. *Einstein (São Paulo).* 2019; 17(2): 1-8.
19. Anunnatsiri S, Chetchoisakd P, Mootsikapun P. Fungemia em pacientes não infectados pelo HIV: uma revisão de cinco anos. *Int J Infect Dis.* 2009; 13 (1): 90-6.
20. Motta AL, Almeida DGM, Almeida Júnior JN, Burattini MN, Rossi, F. Candidemia epidemiologia e susceptibilidade perfil na maior complexo hospital universitário brasileiro. *Braz J Infect Dis.* 2010; 14 (5): 441-8.
21. Colombo AL, Braga T, Silva LR, de Almeida Monfardini LP, Cunha AK, Rady P, et al. estudo prospectivo observacional de candidemia em São Paulo, Brasil: taxa de incidência, epidemiologia e preditores de mortalidade. *Infect Control Hosp Epidemiol.* 2007; 28 (5): 570-6.
22. Almirante B, D Rodriguez, Parque BJ, Cuenca-Estrella H, aplanam SOU, Almela H, et al. ; Barcelona Candidemia Projeto Study Group. Epidemiologia e preditores de mortalidade em casos de infecção de corrente sanguínea Candida: resultados de vigilância de base populacional, Barcelona, Espanha, de 2002 a 2003. *J Clin Microbiol.* 2005; 43 (4): 1829-1835.
23. Costa SF, Marinho I, Araújo EA, Manrique AE, Medeiros EA, Levin AS. fungemiasocomial: um estudo prospectivo de 2 anos. *J Hosp Infect.* 2000; 45 (1): 69-72.
24. Myat TO, Hannaway RF, Zin KN, Htike WW, Win KK, Crump JA, Murdoch DR, Ussher JE. ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014. *Emerging Infectious Diseases.* 2017; 23(5): 857-859.
25. Couto DO, Junior AAP, Farias JLM, Sales DB, Lima JPA, Rodrigues RS, Meneses FA. Associação entre sexo e mortalidade em pacientes com sepse: os hormônios sexuais influenciam o desfecho?. *Revista brasileira de Terapia Intensiva.* 2011; 23 (3): 297-303.
26. Wang HE, Donnelly JP, Shapiro NI, Hohmann SF, Levitan EB. Hospital variations in severe sepsis mortality. *Am J Med Qual.* 2015; 30 (4): 328-336.
27. Sousa MA, Medeiros NM, Carneiro JR, Cardosos AM. Hemoculturas positivas de pacientes da unidade de terapia intensiva de um hospital escola de Goiânia, GO, entre 2010 e 2013. *Estudos, Goiânia.* 2014; 41(3): 627-635.
28. Takeshita N, QuocAnh N, Phuong VT, Thuy, PP, Hough MTL, Takahashi, M and Ohmagari, N. Assessment of Bacteremia in a Large Tertiary Care Hospital in Northern Vietnam: a Single-Center Retrospective Surveillance Study. *Jpn. J. Infect. Dis.* 2019; 72: 118-120.
29. Silva MGC, Rodrigues GS, Gonçalves IL, Grazziotin NA. Distribuição de espécies de Candida e susceptibilidade ao fluconazol de isolados de hemocultivos em hospital regional de Passo Fundo, RS, Brasil. *J. Bras. Patol. Med. Lab.* 2015; 51(3): 158-161.
30. Parajuli NP, Acharya SP, Mishra SK, Parajuli K. Basista Prasad Rijal and Bharat Mani Pokhrel High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. *Antimicrobial Resistance and Infection Control.* 2017; 6:67.
31. Moolchandani K, Sastry AS, Deepashree R, Sisltla S, Harish BM, Mandal J. Antimicrobial Resistance Surveillance among Intensive Care Units of a Tertiary Care Hospital in Southern India. *Journal of Clinical and Diagnostic Research.* 2017; 11(2): 1-7.
32. Ruschel DB, Rodrigues AD, Formolo F. Perfil de resultados de hemoculturas positivas e fatores associados. *RBAC.* 2017; 49(2): 158-63.
33. Arias CA, Contreras GA, Murray BE. Management of multi drug-resistant enterococcal infections. *Clin. Microbiol. Infect.* 2010; 16: 555-562.